hereditary angiodema

ADARx secures $200m to advance clinical programs
ADARx secures $200m to advance clinical programs
Pharmaceutical Technology
ADARx Pharmaceuticals
funding
ADX-324
hereditary angiodema
Flag link:
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Fierce Biotech
Intellia Therapeutics
HAE
hereditary angiodema
CRISPR
NTLA-2002
Flag link:
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Yahoo Finance
Ionis Pharmaceuticals
clinical trials
donidalorsen
hereditary angiodema
HAE
Flag link:
KalVista ends a PhII study early after patients suffer severe and life-threatening side effects
KalVista ends a PhII study early after patients suffer severe and life-threatening side effects
Endpoints
KalVista
KVD824
clinical trials
hereditary angiodema
Flag link:
Intellia's Latest Data Indicate Full Potential of CRISPR
Intellia's Latest Data Indicate Full Potential of CRISPR
BioSpace
Intellia Therapeutics
ATTR amyloidosis
hereditary angiodema
CRISPR
Flag link:
Pharvaris studies of rare disease drug put on hold by FDA
Pharvaris studies of rare disease drug put on hold by FDA
BioPharma Dive
Pharvaris
FDA
hereditary angiodema
HAE
PHA121
Flag link:
CSL reports Phase III data for garadacimab to treat hereditary angioedema
CSL reports Phase III data for garadacimab to treat hereditary angioedema
Clinical Trials Arena
CSL
clinical trials
garadacimab
HAE
hereditary angiodema
Flag link:
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Fierce Pharma
Takeda
CSL
hereditary angiodema
HAE
RWE
Takhzyro
Cinryze
Haegarda
Flag link:
Ionis unveils positive PhII data for in-house rare disease drug, paving way to blockbuster rivalry with Takeda
Ionis unveils positive PhII data for in-house rare disease drug, paving way to blockbuster rivalry with Takeda
Endpoints
Ionis Pharmaceuticals
clinical trials
IONIS-PKK-LRx
hereditary angiodema
Flag link:
Mid-stage angioedema hit sends Kalvista though the roof
Mid-stage angioedema hit sends Kalvista though the roof
EP Vantage
KalVista
HAE
hereditary angiodema
KVD900
Flag link:
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
EP Vantage
Shire
Cinryze
Takhzyro
drug pricing
hereditary angiodema
Flag link:
BioCryst says oral drug works for HAE attacks
BioCryst says oral drug works for HAE attacks
Fierce Biotech
Biocryst
BCX7353
clinical trials
HAE
hereditary angiodema
Flag link:
Shire Secures FDA Approval for HAE Drug Lanadelumab
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Flag link:
Adverum Biotechnologies Receives Orphan Drug Designation for Hereditary Angioedema Gene Therapy Candidate
Adverum Biotechnologies Receives Orphan Drug Designation for Hereditary Angioedema Gene Therapy Candidate
CP Wire
Adverum Biotechnologies
ADVM-053
hereditary angiodema
HAE
FDA
Flag link:
Adverum Biotechnologies Receives Orphan Drug Designation for Hereditary Angioedema Gene Therapy Candidate
Adverum Biotechnologies
ADVM-053
hereditary angiodema
Flag link:
Shire says trial shows new HAE drug significantly reduces attacks
Shire says trial shows new HAE drug significantly reduces attacks
Reuters
Shire
HAE
clinical trials
hereditary angiodema
SHP616
Flag link:
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
Endpoints
FDA
CSL
HAE
hereditary angiodema
Shire
Haegarda
Firazyr
Kalbito
Flag link:
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Fierce Pharma
Shire
rare disease
CSL
patents
Haegarda
HAE
hereditary angiodema
Flag link:
How Does Shire Lead the Angioedema Space?
How Does Shire Lead the Angioedema Space?
Yahoo/Market Realist
Shire
Cinryza
Firazyr
HAE
hereditary angiodema
Flag link:
Dyax banks on drug designation news
Dyax banks on drug designation news
Bizjournals.com
Dyax
DX-2930
HAE
hereditary angiodema
Flag link:

Pages